{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:43:44Z","timestamp":1782888224424,"version":"3.54.5"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T00:00:00Z","timestamp":1406764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0103856","type":"journal-article","created":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T21:09:25Z","timestamp":1406840965000},"page":"e103856","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of the Metabolic Syndrome Risk in Valproate-Treated Patients with Epilepsy and the General Population in Estonia"],"prefix":"10.1371","volume":"9","author":[{"given":"Aleksei","family":"Rakitin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triin","family":"Eglit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulev","family":"K\u00f5ks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margus","family":"Lember","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulev","family":"Haldre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,7,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1468-1331.2006.01268.x","article-title":"Use of antiepileptic drugs in Estonia: an epidemiologic study of adult epilepsy","volume":"13","author":"A Oun","year":"2006","journal-title":"Eur J Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.08.016","article-title":"Metabolic and endocrine effects of valproic acid chronic treatment","volume":"107","author":"V Belcastro","year":"2013","journal-title":"Epilepsy Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000197868","article-title":"Valproate-induced insulin resistance and obesity in children","volume":"71","author":"A Verrotti","year":"2009","journal-title":"Horm Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.yebeh.2006.02.008","article-title":"Insulin-related metabolic changes during treatment with valproate in patients with epilepsy","volume":"8","author":"V Pylvanen","year":"2006","journal-title":"Epilepsy Behav"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diabetes.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"GM Reaven","year":"1988","journal-title":"Diabetes"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2458-11-4","article-title":"Prevalence of the metabolic syndrome in Luxembourg according to the Joint Interim Statement definition estimated from the ORISCAV-LUX study","volume":"11","author":"A Alkerwi","year":"2011","journal-title":"BMC Public Health"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1017\/S1368980010003320","article-title":"The prevalence of metabolic syndrome in Latin America: a systematic review","volume":"14","author":"F Marquez-Sandoval","year":"2011","journal-title":"Public Health Nutr"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1471-2458-7-220","article-title":"Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study","volume":"7","author":"B Hildrum","year":"2007","journal-title":"BMC Public Health"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/1471-2458-11-562","article-title":"Prevalence of metabolic syndrome in Murcia Region, a southern European Mediterranean area with low cardiovascular risk and high obesity","volume":"11","author":"D Gavrila","year":"2011","journal-title":"BMC Public Health"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/met.2008.0068","article-title":"Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia","volume":"7","author":"K Gundogan","year":"2009","journal-title":"Metab Syndr Relat Disord"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"951672","DOI":"10.1155\/2012\/951672","article-title":"Metabolic syndrome in estonia: prevalence and associations with insulin resistance","volume":"2012","author":"T Eglit","year":"2012","journal-title":"Int J Endocrinol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1528-1167.2009.02206.x","article-title":"The metabolic syndrome in overweight epileptic patients treated with valproic acid","volume":"51","author":"A Verrotti","year":"2010","journal-title":"Epilepsia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.seizure.2012.06.001","article-title":"Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate","volume":"21","author":"J Fang","year":"2012","journal-title":"Seizure"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"AT Berg","year":"2010","journal-title":"Epilepsia"},{"key":"ref15","article-title":"CLSI. Measurement procedure comparison and bias estimation using patient samples; Approved guideline-Third edition. CLSI document EP09-A3","author":"P Wayne","year":"2013","journal-title":"Clinical and laboratory standards institute"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.crd.0000380842.14048.7e","article-title":"Diagnosis and management of the metabolic syndrome. An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary","volume":"13","author":"SM Grundy","year":"2005","journal-title":"Cardiol Rev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0404.1984.tb00804.x","article-title":"Weight gain during treatment with valproate","volume":"70","author":"H Dinesen","year":"1984","journal-title":"Acta Neurol Scand"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ana.410390506","article-title":"Obesity and endocrine disorders in women taking valproate for epilepsy","volume":"39","author":"JI Isojarvi","year":"1996","journal-title":"Ann Neurol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1046\/j.1528-1157.2001.0420081002.x","article-title":"Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy","volume":"42","author":"LJ Stephen","year":"2001","journal-title":"Epilepsia"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1212\/WNL.56.2.172","article-title":"Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy","volume":"56","author":"V Biton","year":"2001","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.seizure.2006.12.009","article-title":"Valproate, weight gain and carbohydrate craving: a gender study","volume":"16","author":"F El-Khatib","year":"2007","journal-title":"Seizure"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00415-002-0731-3","article-title":"Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women","volume":"249","author":"G Luef","year":"2002","journal-title":"J Neurol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1111\/j.1467-789X.2010.00800.x","article-title":"Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications","volume":"12","author":"A Verrotti","year":"2011","journal-title":"Obes Rev"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bmj.283.6291.577","article-title":"Effects of sodium valproate in 100 children with special reference to weight","volume":"283","author":"J Egger","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1528-1167.2006.00546.x","article-title":"Characterization of insulin secretion in Valproate-treated patients with epilepsy","volume":"47","author":"V Pylvanen","year":"2006","journal-title":"Epilepsia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1212\/01.WNL.0000048209.07526.86","article-title":"Fasting serum insulin and lipid levels in men with epilepsy","volume":"60","author":"V Pylvanen","year":"2003","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/msj.20212","article-title":"Insulin resistance in obesity as the underlying cause for the metabolic syndrome","volume":"77","author":"EJ Gallagher","year":"2010","journal-title":"Mt Sinai J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1475-2840-10-93","article-title":"Predicting insulin resistance using the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults","volume":"10","author":"JK Chiang","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"ref29","first-page":"E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"RA DeFronzo","year":"1979","journal-title":"Am J Physiol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archinte.163.4.427","article-title":"The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988\u20131994","volume":"163","author":"YW Park","year":"2003","journal-title":"Arch Intern Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1528-1157.1996.tb00557.x","article-title":"Leisure time activity and physical fitness in patients with epilepsy","volume":"37","author":"BJ Steinhoff","year":"1996","journal-title":"Epilepsia"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0103856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T08:52:42Z","timestamp":1649839962000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0103856"}},"subtitle":[],"editor":[{"given":"Maria Eugenia","family":"Saez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,31]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0103856","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,31]]}}}